<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-TOQWBX3M/64c-2cffc-5f574b1952--67431593b3bb60/PDF"><dcterms:extent>645 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-TOQWBX3M/65751759-4613-4bc6-bfc5-22393bb04fcf/TEXT"><dcterms:extent>53 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2021-2024"><edm:begin xml:lang="en">2021</edm:begin><edm:end xml:lang="en">2024</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-TOQWBX3M"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-07XDMEIG" /><dcterms:issued>2024</dcterms:issued><dc:creator>Gidwani, Kamlesh</dc:creator><dc:creator>Gregorčič, Neža</dc:creator><dc:contributor>Gregorčič, Neža</dc:contributor><dc:creator>Jain, Shruti</dc:creator><dc:format xml:lang="sl">številka:6</dc:format><dc:format xml:lang="sl">str. 61-74</dc:format><dc:identifier>COBISSID_HOST:210376707</dc:identifier><dc:identifier>ISSN:2670-4463</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-TOQWBX3M</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Slovensko združenje za klinično kemijo in laboratorijsko medicino</dc:publisher><dcterms:isPartOf xml:lang="sl">Laboratorijska medicina</dcterms:isPartOf><dc:subject xml:lang="en">biomarker</dc:subject><dc:subject xml:lang="en">cancer (medicine)</dc:subject><dc:subject xml:lang="sl">fluorescenca s časovnim zamikom</dc:subject><dc:subject xml:lang="sl">glikozilacija</dc:subject><dc:subject xml:lang="en">glycosylation</dc:subject><dc:subject xml:lang="en">lectins</dc:subject><dc:subject xml:lang="sl">lektini</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="en">time-resolved fluorescence</dc:subject><dcterms:temporal rdf:resource="2021-2024" /><dc:title xml:lang="sl">Aberrant glycosylation as a biomarker in oncology| Spremembe v glikozilaciji kot biomarker v onkologiji|</dc:title><dc:description xml:lang="sl">Cancer represents a significant global health challenge, with nearly 20 million new cases and over 9 million deaths annually. Early diagnosis is a key factor in improving survival rates, yet current diagnostic methods lack sensitivity, specificity, and accessibility. Glycosylation patterns of biomarkers offer a promising target for early detection of cancer and the development of personalized treatment strategies. The europium-doped nanoparticle-based glycovariant assay represents a novel approach that leverages time-resolved fluorescence for enhanced sensitivity and glycan moiety recognition for enhanced specificity. This review explores glycosylation changes in cancer, emphasizing their potential as diagnostic tools, with a particular focus on the europiumdoped nanoparticle-based glycovariant assay. The assay has demonstrated potential for identifying specific cancer-associated glycovariants in ovarian, prostate, breast, colorectal, and bladder cancers. The assay has the capacity to distinguish cancer-specific glycovariants from nonmalignant sources. However, further optimization and bigger sample cohorts are necessary to enhance the diagnostic utility of the assay</dc:description><dc:description xml:lang="sl">Rak je s skoraj 20 milijoni novih primerov in 9 milijoni smrti letno znatni izziv globalnemu zdravju. Za izboljšanje stopnje preživetja je ključna zgodnja diagnoza, vendar so trenutne diagnostične metode, kar se tiče občutljivosti, specifičnosti in dostopnosti, pomanjkljive. Spremembe v glikozilaciji biomarkerjev nudijo obetavno možnost za zgodnje odkritje in izdelavo personaliziranih strategij zdravljenja. Analiza glikovariant s pomočjo z evropijem polnjenih nanodelcev je nov pristop, ki uporablja fluorescenco s časovnim zamikom za povečano občutljivost in prepoznavanje sladkorne komponente molekul za večjo specifičnost. Članek se osredotoča na spremembe glikozilacij pri raku s poudarkom na njihovem diagnostičnem potencialu in metodah, v ospredju je s pomočjo z evropijem polnjenih nanodelcev. Ta metoda kaže visok potencial za identifikacijo določenih glikovariant, ki jih povezujemo z rakom jajčnikov, prostate, dojk, črevesja in mehurja. Zmožnost razlikovanja za raka specifičnih glikovariant in glikovariant nemalignega izvora odpira vrata za izboljšano obravnavo onkoloških pacientov. Za večjo uporabnost metode pa so še vedno potrebne optimizacije in analiza z večjim številom vzorcev</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-TOQWBX3M"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-TOQWBX3M" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-TOQWBX3M/64c-2cffc-5f574b1952--67431593b3bb60/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:dataProvider xml:lang="en">National and University Library of Slovenia</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-TOQWBX3M/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-TOQWBX3M" /></ore:Aggregation></rdf:RDF>